<?xml version="1.0" encoding="Windows-1252"?>
<rss version="2.0">
    <channel>
        <title>Xagena Medicina</title>
        <description>Discussione di argomenti medico-farmacologici</description>
        <link>http://blog.libero.it/XagenaMedicina/</link>
        <lastBuildDate>Fri, 26 Apr 2013 01:54:16 +0200</lastBuildDate>
        <generator>Libero Blog</generator>
        <category>Salute e Benessere</category>
        <category>Medicina</category>
        <item>
            <title>Terapia farmacologica: Parte 2</title>
            <link>http://blog.libero.it/XagenaMedicina/12061318.html</link>
            <description>&lt;div&gt;&lt;a style=&quot;COLOR: rgb(0,0,204); TEXT-DECORATION: none&quot; href=&quot;http://www.farmaexplorer.it/articolo/3576&quot; target=&quot;_blank&quot;&gt;&lt;font class=&quot;ske04&quot;&gt;Apixaban versus Aspirina nei pazienti con fibrillazione atriale e precedente ictus o attacco ischemico transitorio&lt;/font&gt;&lt;/a&gt;&lt;div style=&quot;TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 14px/21px sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;excerpt&quot;&gt;&lt;p style=&quot;MARGIN: 1em 0px&quot;&gt;&lt;font class=&quot;ske04&quot;&gt;Nello studio AVERROES, Apixaban ( Eliquis ), un nuovo inibitore del fattore Xa, ha ridotto il rischio di ictus o di embolia sistemica nei pazienti con fibrillazione atriale ad alto rischio di ictus, ma non-idonei alla terapia con antagonisti della ...&lt;span class=&quot;Apple-converted-space&quot;&gt; &lt;/span&gt;&lt;span&gt;&lt;a style=&quot;COLOR: rgb(0,0,204); TEXT-DECORATION: none&quot; href=&quot;http://www.farmaexplorer.it/articolo/3576&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;&lt;/font&gt;&lt;/p&gt;&lt;span&gt;&lt;a style=&quot;COLOR: rgb(0,0,204); TEXT-DECORATION: none&quot; href=&quot;http://www.farmaexplorer.it/articolo/10086&quot; target=&quot;_blank&quot;&gt;&lt;font class=&quot;ske04&quot;&gt;Effetto a lungo termine dell'Aspirina sul rischio di cancro nei portatori di carcinoma colorettale ereditario&lt;/font&gt;&lt;/a&gt;&lt;div style=&quot;TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 14px/21px sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;excerpt&quot;&gt;&lt;p style=&quot;MARGIN: 1em 0px&quot;&gt;&lt;font class=&quot;ske04&quot;&gt;Studi osservazionali riferiscono meno carcinomi colorettali nei consumatori abituali di Acido Acetilsalicilico ( Aspirina ) e studi randomizzati e controllati hanno mostrato un ridotto rischio di adenomi ma nessuno ha previsto la prevenzione del ...&lt;span class=&quot;Apple-converted-space&quot;&gt; &lt;/span&gt;&lt;span&gt;&lt;a style=&quot;COLOR: rgb(0,0,204); TEXT-DECORATION: none&quot; href=&quot;http://www.farmaexplorer.it/articolo/10086&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;&lt;/font&gt;&lt;/p&gt;&lt;span&gt;&lt;a style=&quot;COLOR: rgb(0,0,204); TEXT-DECORATION: none&quot; href=&quot;http://www.farmaexplorer.it/articolo/1993&quot; target=&quot;_blank&quot;&gt;&lt;font class=&quot;ske04&quot;&gt;Interruzione di Aspirina a basso dosaggio e rischio di infarto del miocardio&lt;/font&gt;&lt;/a&gt;&lt;div style=&quot;TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 14px/21px sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;excerpt&quot;&gt;&lt;p style=&quot;MARGIN: 1em 0px&quot;&gt;&lt;font class=&quot;ske04&quot;&gt;Uno studio nidificato caso-controllo ha valutato il rischio di infarto miocardico e morte per malattia coronarica dopo la sospensione di Aspirina ( Acido Acetilsalicilico ) a basso dosaggio nei pazienti sottoposti a cure primarie con una storia di ...&lt;span class=&quot;Apple-converted-space&quot;&gt; &lt;/span&gt;&lt;span&gt;&lt;a style=&quot;COLOR: rgb(0,0,204); TEXT-DECORATION: none&quot; href=&quot;http://www.farmaexplorer.it/articolo/1993&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</description>
        <category>Acetilsalicilico ( Aspirina )</category>
        <category>Apixaban ( Eliquis )</category>
        <category>Apixaban versus Aspirina</category>
        <category>Aspirina a basso dosaggio</category>
        <category>Aspirina: rischio di cancro</category>
        <category>Attacco ischemico transitorio</category>
        <category>fibrillazione atriale</category>
        <category>Fibrillazione Newsletter</category>
        <category>ictus</category>
        <category>Infarto del miocardio</category>
        <category>Infarto Newsletter</category>
        <category>Inibitore del fattore Xa</category>
        <category>Rischio di embolia sistemica</category>
        <category>Rischio di ictus</category>
        <category>Studio AVERROES</category>
        <category>Tumore colorettale ereditario</category>
        <category>Tumori colorettali</category>
            <pubDate>Fri, 26 Apr 2013 01:54:16 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/12061318.html</guid>
        </item>
        <item>
            <title>Terapia farmacologica - Parte 1</title>
            <link>http://blog.libero.it/XagenaMedicina/12057917.html</link>
            <description>&lt;a href=&quot;http://www.farmaexplorer.it/articolo/20301&quot; target=&quot;_blank&quot;&gt;&lt;font face=&quot;arial, helvetica, sans-serif&quot; class=&quot;ske04&quot; color=&quot;#ff0000&quot;&gt;&lt;b&gt;Sofosbuvir, Ledipasvir, e Ribavirina nella infezione da HCV genotipo 1: il regime a tripla combinazione ha prodotto una SVR12 del 100%&lt;/b&gt;&lt;/font&gt;&lt;/a&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;font class=&quot;ske03&quot; face=&quot;arial, helvetica, sans-serif&quot;&gt;Un regime senza Interferone a base di Sofosbuvir, Ledipasvir, e Ribavirina ha prodotto una risposta virologica sostenuta a 12 settimane ( SVR12 ) del 100% sia per i pazienti naive al trattamento ( mai trattati ) sia per i pazienti con genotipo 1 in ... &lt;a href=&quot;http://www.farmaexplorer.it/articolo/20301&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/20409&quot; target=&quot;_blank&quot;&gt;&lt;font face=&quot;arial, helvetica, sans-serif&quot; class=&quot;ske04&quot;&gt;&lt;b&gt;Farmaci per la sclerosi multipla: Tysabri e trombocitopenia&lt;/b&gt;&lt;/font&gt;&lt;/a&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;font class=&quot;ske03&quot; face=&quot;arial, helvetica, sans-serif&quot;&gt;Natalizumab ( Tysabri ) è un anticorpo monoclonale diretto contro l'integrina alfa4beta1, che impedisce l'adesione e la migrazione linfocitaria dal letto vascolare al sistema nervoso centrale e all’intestino. In Italia, Natalizumab è ... &lt;a href=&quot;http://www.farmaexplorer.it/articolo/20409&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/20416&quot; target=&quot;_blank&quot;&gt;&lt;font face=&quot;arial, helvetica, sans-serif&quot; class=&quot;ske04&quot;&gt;&lt;b&gt;Approvato dalla Food and Drug Administration il primo antidoto contro la Tossina botulinica&lt;/b&gt;&lt;/font&gt;&lt;/a&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;font class=&quot;ske03&quot; face=&quot;arial, helvetica, sans-serif&quot;&gt;L’Agenzia regolatoria statunitense, FDA ( Food and Drug Administration ), ha annunciato di aver approvato il primo antidoto contro la Tossina botulinica, un’antitossina verso sette sierotipi di tossina botulinica che possono causare la malattia ... &lt;a href=&quot;http://www.farmaexplorer.it/articolo/20416&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</description>
        <category>anticorpo monoclonale</category>
        <category>Antidoti Newsletter</category>
        <category>Epatite C Newsletter</category>
        <category>Epatite C: Ribavirina</category>
        <category>Farmaci epatite C Newsletter</category>
        <category>Farmaci per sclerosi multipla</category>
        <category>Infezione da HCV genotipo 1</category>
        <category>Integrina alfa4beta1</category>
        <category>Ledipasvir</category>
        <category>medicina xagena</category>
        <category>Natalizumab ( Tysabri )</category>
        <category>Regime a tripla combinazione</category>
        <category>Regime senza Interferone</category>
        <category>ribavirina</category>
        <category>Sofosbuvir</category>
        <category>Sofosbuvir Ledipasvir</category>
        <category>tossina botulinica</category>
        <category>Tysabri e trombocitopenia</category>
            <pubDate>Wed, 24 Apr 2013 01:30:32 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/12057917.html</guid>
        </item>
        <item>
            <title>Farmaci per combattere l'abitudine al fumo</title>
            <link>http://blog.libero.it/XagenaMedicina/12055989.html</link>
            <description>&lt;a href=&quot;http://www.farmaexplorer.it/articolo/1581&quot; target=&quot;_blank&quot;&gt;&lt;font color=&quot;#ff0000&quot; class=&quot;ske04&quot; face=&quot;arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;Reazioni avverse da farmaci: negli Stati Uniti aumenta il ricorso alla class action per chiedere risarcimenti alle società farmaceutiche&lt;/strong&gt;&lt;/font&gt;&lt;/a&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;font face=&quot;arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;Il ruolo sempre maggiore del cittadino nel processo terapeutico ha come conseguenza l’aumento di cause legali nei confronti delle società che producono farmaci. Negli Stati Uniti, il caso più eclatante è quello del Vioxx. ... &lt;span&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/1581&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/20540&quot; target=&quot;_blank&quot;&gt;&lt;font color=&quot;#ff0000&quot; class=&quot;ske04&quot; face=&quot;arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;Vareniclina per smettere di fumare e rischio di gravi eventi cardiovascolari&lt;/strong&gt;&lt;/font&gt;&lt;/a&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;font face=&quot;arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;Uno studio di coorte danese ha verificato se la Vareniclina ( Champix, Chantix ) fosse associata a un aumentato rischio di gravi eventi cardiovascolari rispetto a un altro farmaco usato per smettere di fumare, Bupropione ( Zyban ).Hanno preso parte ... &lt;span&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/20540&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;span&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/16281&quot; target=&quot;_blank&quot;&gt;&lt;font color=&quot;#ff0000&quot; class=&quot;ske04&quot; face=&quot;arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;Farmaci antifumo e rischi cardiaci&lt;/strong&gt;&lt;/font&gt;&lt;/a&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;font face=&quot;arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;Una meta-analisi di studi clinici randomizzati ha mostrato che coloro che assumono Vareniclina ( Chantix; in Italia: Champix ), un farmaco per smettere di fumare, presentano un piccolo incremento, ma statisticamente significativo, del rischio di ... &lt;span&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/16281&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;</description>
        <category>Bupropione ( Zyban )</category>
        <category>eventi cardiovascolari</category>
        <category>Farmaci antifumo</category>
        <category>farmaci e rischi cardiaci</category>
        <category>Farmaci: class action</category>
        <category>Farmacologia Newsletter</category>
        <category>Il caso Vioxx</category>
        <category>Newsletter Farmaci psichiatrici</category>
        <category>Newsletter farmacologia</category>
        <category>Newsletter Tabagismo</category>
        <category>Reazioni da farmaci</category>
        <category>Smettere di fumare</category>
        <category>Società farmaceutiche</category>
        <category>Vareniclina ( Champix )</category>
        <category>vareniclina ( Chantix )</category>
        <category>Vareniclina: fumo</category>
            <pubDate>Tue, 23 Apr 2013 02:00:52 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/12055989.html</guid>
        </item>
        <item>
            <title>Neurologia Notizie</title>
            <link>http://blog.libero.it/XagenaMedicina/12026475.html</link>
            <description>&lt;p&gt;&lt;a href=&quot;http://mediexplorer.it/articolo/18689&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;La vaccinazione contro la febbre gialla aumenta il tasso di recidiva di sclerosi multipla&lt;/span&gt; &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske06&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;Un piccolo studio prospettico ha mostrato che i pazienti con sclerosi multipla recidivante-remittente hanno presentato un aumento maggiore di 10 volte del tasso di ricaduta della malattia dopo aver ricevuto la vaccinazione contro la febbre ... &lt;/strong&gt;&lt;/span&gt;&lt;a href=&quot;http://mediexplorer.it/articolo/18689&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;a href=&quot;http://mediexplorer.it/articolo/19728&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Uso di FANS e rischio di malattia di Parkinson&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske06&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;Per valutare la relazione tra la malattia di Parkinson e l'uso precedente di anti-infiammatori non-steroidei ( FANS ) in un'ampia coorte di uomini &amp;egrave; stato elaborato uno studio caso-controllo nidificato.Hanno partecipato 22.007 medici di sesso ... &lt;/strong&gt;&lt;/span&gt;&lt;a href=&quot;http://mediexplorer.it/articolo/19728&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;a href=&quot;http://mediexplorer.it/articolo/20157&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Abitudine al fumo durante la mezza et&amp;agrave; e rischio a lungo termine di malattia di Alzheimer e demenza vascolare &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske06&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;Il fumo &amp;egrave; un fattore di rischio per diverse malattie minaccianti la vita, ma la sua associazione a lungo termine con la demenza &amp;egrave; controversa e poco studiata. L'obiettivo di uno studio &amp;egrave; stato quello di indagare l'associazione a ... &lt;/strong&gt;&lt;/span&gt;&lt;a href=&quot;http://mediexplorer.it/articolo/20157&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/p&gt;</description>
        <category>Abitudine al fumo</category>
        <category>Demenza Newsletter</category>
        <category>FANS e malattia di Parkinson</category>
        <category>Fumo durante mezza età</category>
        <category>Malattie minaccianti la vita</category>
        <category>Malattie Neurologiche Newsletter</category>
        <category>Medicina Newsletter</category>
        <category>MediExplorer Newsletter</category>
        <category>Medilearn Newsletter</category>
        <category>Parkinson Newsletter</category>
        <category>Recidiva sclerosi multipla</category>
        <category>Rischio demenza vascolare</category>
        <category>Rschio malattia di Alzheimer</category>
        <category>Vaccinazione febbre gialla</category>
        <category>Vaccini sclerosi multipla</category>
        <category>Xapedia Newsletter</category>
            <pubDate>Sat, 06 Apr 2013 18:07:29 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/12026475.html</guid>
        </item>
        <item>
            <title>Neurologia News</title>
            <link>http://blog.libero.it/XagenaMedicina/11965053.html</link>
            <description>&lt;p&gt;&lt;a href=&quot;http://www.parkinsononline.net/index.php?view=21493&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Freezing della deambulazione nella malattia di Parkinson&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&amp;Egrave; stato descritto il fenotipo Levodopa-indotto di stato on di freezing della deambulazione ( blocco motorio ) nella malattia di Parkinson.&amp;Egrave; stato presentato un approccio diagnostico per separare lo stato on di freezing della deambulazione ( deterioramento durante lo stato on ) da altre forme di freezing della andatura.Quattro pazienti con malattia di [...] &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;a href=&quot;http://www.parkinsononline.net/?view=21493&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;a href=&quot;http://www.alzheimeronline.net/index.php?view=19799&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Livello di emoglobina in persone anziane e malattia di Alzheimer incidente&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&amp;Egrave; stato condotto uno studio per testare l&amp;rsquo;ipotesi che il livello di emoglobina sia associato alla malattia di Alzheimer incidente.In totale, 881 persone anziane che partecipavano al Rush Memory and Aging Project, senza demenza e con misurazione del livello di emoglobina, sono state sottoposte a cadenza annuale a valutazioni cognitive e cliniche per malattia di Alz [...] &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;a href=&quot;http://www.alzheimeronline.net/?view=19799&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;a href=&quot;http://mediexplorer.it/articolo/21237&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Tossina botulinica A per il trattamento profilattico di emicrania e mal di testa di tipo tensivo negli adulti&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske06&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;La Tossina botulinica A ( Botox ) &amp;egrave; approvata dalla Food and Drug Administration ( FDA ) statunitense per il trattamento profilattico dell&amp;rsquo;emicrania cronica.&amp;Egrave; stata effettuata una meta-analisi per valutare questa tossina per il ... &lt;/strong&gt;&lt;a href=&quot;http://mediexplorer.it/articolo/21237&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</description>
        <category>botox</category>
        <category>Emicrania cronica</category>
        <category>Emoglobina e anziani</category>
        <category>Farmaci Newsletter</category>
        <category>Freezing deambulazione</category>
        <category>levodopa</category>
        <category>malattia di alzheimer</category>
        <category>malattia di parkinson</category>
        <category>Medicina Newsletter</category>
        <category>medicina xagena</category>
        <category>terapia emicrania</category>
        <category>Terapia mal di testa</category>
        <category>Tossina botulinica A</category>
        <category>Trattamento profilattico</category>
            <pubDate>Wed, 06 Mar 2013 23:16:34 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11965053.html</guid>
        </item>
        <item>
            <title>Medicina: infarto miocardico, diabete mellito</title>
            <link>http://blog.libero.it/XagenaMedicina/11965041.html</link>
            <description>&lt;div class=&quot;video&quot;&gt;&lt;div class=&quot;video-content&quot;&gt;&lt;a href=&quot;http://www.medtv.it/index/show/id/86&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske05&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Omega 3 non associati a beneficio nella prevenzione dell'infarto miocardico e dell'ictus nel post-IMA&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;video&quot;&gt;&lt;div class=&quot;video-content&quot;&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span class=&quot;ske06&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;span class=&quot;ske05&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;video&quot;&gt;&lt;div class=&quot;video-content&quot;&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;a href=&quot;http://www.medtv.it/index/show/id/84&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske05&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Le statine associate a un aumento del rischio di diabete mellito nelle donne in postmenopausa&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class=&quot;ske05&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</description>
        <category>Donne in postmenopausa</category>
        <category>Ictus nel post-IMA</category>
        <category>Ictus Newsletter</category>
        <category>Infarto del miocardio</category>
        <category>Infarto miocardico e ictus</category>
        <category>Infarto Newsletter</category>
        <category>Medicina Newsletter</category>
        <category>Omega 3 e infarto</category>
        <category>Prevenzione infarto</category>
        <category>Rischio di diabete mellito</category>
        <category>Statine e diabete mellito</category>
            <pubDate>Wed, 06 Mar 2013 23:10:08 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11965041.html</guid>
        </item>
        <item>
            <title>Asma Notizie</title>
            <link>http://blog.libero.it/XagenaMedicina/11906085.html</link>
            <description>&lt;div&gt;&lt;div class=&quot;post&quot;&gt;&lt;a href=&quot;http://www.medpedia.it/medicina/asma/20560-la-termoplastica-bronchiale-una-nuova-opzione-terapeutica-per-l-asma-grave&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;La termoplastica bronchiale, una nuova opzione terapeutica per l&amp;rsquo;&lt;span class=&quot;highlight&quot;&gt;asma&lt;/span&gt; grave&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span style=&quot;font-family: Verdana;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-excerpt&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;A causa dei limiti dei farmaci attualmente in commercio, persiste una significativa esigenza medica insoddisfatta per migliorare l&amp;rsquo;assistenza dei pazienti affetti da asma grave mediante un miglior controllo dei sintomi dell&amp;rsquo;asma. Il sistema di termoplastica bronchiale... [&lt;span class=&quot;read-more&quot;&gt;&lt;a href=&quot;http://www.medpedia.it/medicina/asma/20560-la-termoplastica-bronchiale-una-nuova-opzione-terapeutica-per-l-asma-grave&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;] &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-excerpt&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;a href=&quot;http://www.medpedia.it/medicina/asma/21184-la-gravita-del-punteggio-dell-asma-predice-gli-esiti-clinici-in-pazienti-con-asma-persistente-da-moderata-a-grave-2012&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span class=&quot;ske04&quot;&gt;La gravit&amp;agrave; del punteggio dell&amp;rsquo;&lt;span class=&quot;highlight&quot;&gt;asma&lt;/span&gt; predice gli esiti clinici in pazienti con &lt;span class=&quot;highlight&quot;&gt;asma&lt;/span&gt; persistente da moderata a grave&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span style=&quot;font-family: Verdana;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-excerpt&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;Il punteggio di gravit&amp;agrave; dell'asma ( SOA; severity of asthma ) si basa su un questionario validato malattia-specifico che affronta la frequenza dei sintomi dell'asma, l'uso di corticosteroidi per via sistemica, l'uso di altri farmaci per l'asma e la storia di ospedalizzazione /... [&lt;span class=&quot;read-more&quot;&gt;&lt;a href=&quot;http://www.medpedia.it/medicina/asma/21184-la-gravita-del-punteggio-dell-asma-predice-gli-esiti-clinici-in-pazienti-con-asma-persistente-da-moderata-a-grave-2012&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;] &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-excerpt&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;a href=&quot;http://www.medpedia.it/medicina/asma/21196-la-combinazione-fluticasone-e-salmeterolo-apporta-benefici-nei-fumatori-con-asma&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span class=&quot;ske04&quot;&gt;La combinazione Fluticasone e Salmeterolo apporta benefici nei fumatori con &lt;span class=&quot;highlight&quot;&gt;asma&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span style=&quot;font-family: Verdana;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-excerpt&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;Il fumo induce infiammazione delle vie aeree e relativa resistenza agli steroidi per via inalatoria.L'obiettivo di uno studio &amp;egrave; stato quello di valutare gli effetti sull'iperreattivit&amp;agrave; delle vie aeree aggiungendo Salmeterolo a Fluticasone rispetto al raddoppio... [&lt;span class=&quot;read-more&quot;&gt;&lt;a href=&quot;http://www.medpedia.it/medicina/asma/21196-la-combinazione-fluticasone-e-salmeterolo-apporta-benefici-nei-fumatori-con-asma&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;]&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-excerpt&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-excerpt&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</description>
        <category>Asma grave: farmaci</category>
        <category>Asma Newsletter</category>
        <category>Asma persistente</category>
        <category>Asma Xagena</category>
        <category>Farmaci per asma</category>
        <category>fluticasone</category>
        <category>Fluticasone e Salmeterolo</category>
        <category>Fumatori con asma</category>
        <category>Fumo e infiammazione</category>
        <category>Infiammazione vie aeree</category>
        <category>pneumologia xagena</category>
        <category>salmeterolo</category>
        <category>Steroidi per via inalatoria</category>
        <category>Terapia asma grave</category>
        <category>Termoplastica bronchiale</category>
            <pubDate>Sat, 09 Feb 2013 14:14:15 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11906085.html</guid>
        </item>
        <item>
            <title>Farmaci per la sclerosi multipla: Tysabri</title>
            <link>http://blog.libero.it/XagenaMedicina/11860447.html</link>
            <description>&lt;p&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/17689&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Sclerosi multipla: associazione fra Natalizumab e leucoencefalopatia multifocale progressiva &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;Al 20 gennaio 2010, fra i pazienti con sclerosi multipla in trattamento con Natalizumab ( Tysabri ) sono stati segnalati 31 casi di leucoencefalopatia multifocale progressiva ( PML ) su circa 66.000 soggetti esposti.Il rischio di sviluppare PML ... &lt;/span&gt;&lt;/strong&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/17689&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;Leggi&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/17754&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span class=&quot;ske04&quot;&gt;Sicurezza ed efficacia di Natalizumab nei pazienti pediatrici con sclerosi multipla&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;Uno studio ha descritto l'effetto di Natalizumab ( Tysabri ) nel trattamento di persone con sclerosi multipla attiva trattate prima dei 18 anni di et&amp;agrave;. In totale, 19 pazienti pediatrici con sclerosi multipla ( et&amp;agrave; media 14.6 anni, ... &lt;/span&gt;&lt;/strong&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/17754&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;Leggi&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/18433&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Risposta immunitaria al virus JC in pazienti con sclerosi multipla trattati con Natalizumab&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;Natalizumab ( Tysabri ) &amp;egrave; utilizzato per la prevenzione delle ricadute e della progressione della disabilit&amp;agrave; in pazienti con sclerosi multipla, ma &amp;egrave; stato associato a leucoencefalopatia multifocale progressiva.&amp;Egrave; stato ... &lt;/span&gt;&lt;/strong&gt;&lt;a href=&quot;http://www.farmaexplorer.it/articolo/18433&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;Leggi&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/div&gt;</description>
        <category>Farmaci: Natalizumab</category>
        <category>Leucoencefalopatia multifocale</category>
        <category>medicina xagena</category>
        <category>natalizumab</category>
        <category>Natalizumab ( Tysabri )</category>
        <category>Neurologia Newsletter</category>
        <category>neurologia xagena</category>
        <category>pazienti pediatrici</category>
        <category>Rischio PML</category>
        <category>sclerosi multipla</category>
        <category>virus JC</category>
            <pubDate>Mon, 21 Jan 2013 00:51:51 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11860447.html</guid>
        </item>
        <item>
            <title>Oncologia: novità sulla terapia dei tumori</title>
            <link>http://blog.libero.it/XagenaMedicina/11849085.html</link>
            <description>&lt;div&gt;&lt;li class=&quot;sa_wr&quot;&gt;&lt;div class=&quot;sa_cc&quot;&gt;&lt;div class=&quot;sa_mc&quot;&gt;&lt;div class=&quot;sb_tlst&quot;&gt;&lt;a href=&quot;http://www.oncologiamedica.net/&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #663399;&quot;&gt;&lt;span class=&quot;ske05&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Oncologia&lt;/strong&gt; Medica - Le Novita' in &lt;strong&gt;Oncologia&lt;/strong&gt; - OncologiaMedica.net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;sb_meta&quot;&gt;&lt;cite&gt;&lt;span style=&quot;font-family: Arial; color: #388222;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;www.&lt;strong&gt;oncologia&lt;/strong&gt;medica.net&lt;/span&gt;&lt;/span&gt;&lt;/cite&gt;&lt;/div&gt;&lt;p&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Oncologia&lt;/strong&gt; Medica - le novit&amp;agrave; in &lt;strong&gt;oncologia&lt;/strong&gt;. ... Nonostante la mancanza di miglioramenti importanti nel trattamento della mielofibrosi primaria, sono emerse recenti ...&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/li&gt;&lt;li class=&quot;sa_wr&quot;&gt;&lt;div class=&quot;sa_cc&quot;&gt;&lt;div class=&quot;sa_mc&quot;&gt;&lt;div class=&quot;sb_tlst&quot;&gt;&lt;a href=&quot;http://www.oncologiaonline.net/&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #663399;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Oncologia&lt;/strong&gt;, approfondimenti in &lt;strong&gt;Oncologia&lt;/strong&gt; - OncologiaOnline.net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;sb_meta&quot;&gt;&lt;cite&gt;&lt;span style=&quot;font-family: Arial; color: #388222;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;www.&lt;strong&gt;oncologia&lt;/strong&gt;online.net&lt;/span&gt;&lt;/span&gt;&lt;/cite&gt;&lt;/div&gt;&lt;p&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Oncologia&lt;/strong&gt;, approfondimenti in &lt;strong&gt;Oncologia&lt;/strong&gt;. ... Sono stati pubblicati i risultati di due studi di fase III riguardanti Regorafenib ( Stivarga ), un inibitore ...&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/li&gt;&lt;/div&gt;</description>
        <category>medicina xagena</category>
        <category>mielofibrosi</category>
        <category>Novità in Oncologia</category>
        <category>oncologia</category>
        <category>oncologia medica</category>
        <category>Oncologia News</category>
        <category>oncologia online</category>
        <category>oncologia xagena</category>
        <category>Regorafenib</category>
        <category>Stivarga</category>
            <pubDate>Tue, 15 Jan 2013 11:54:25 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11849085.html</guid>
        </item>
        <item>
            <title>Cardiologia: novità sulle malattie cardiovascolari</title>
            <link>http://blog.libero.it/XagenaMedicina/11845855.html</link>
            <description>&lt;div&gt;&lt;li class=&quot;sa_wr&quot;&gt;&lt;div class=&quot;sa_cc&quot;&gt;&lt;div class=&quot;sa_mc&quot;&gt;&lt;a href=&quot;http://www.cardiologia.net/&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #663399;&quot;&gt;&lt;span class=&quot;ske06&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span class=&quot;ske05&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Cardiologia&lt;/strong&gt;.&lt;strong&gt;net&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;cite&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&amp;nbsp; - &lt;/span&gt;&lt;/span&gt;&lt;a href=&quot;http://www.cardiologia.net&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;www.cardiologia.net&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt; - &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/cite&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Cardiologia&lt;/strong&gt;, &lt;strong&gt;infarto, malattie del cuore, articoli sulla diagnosi, trattamento e cura, farmacologica o chirurgica, delle malattie cardiovascolari.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/li&gt;&lt;/div&gt;&lt;p class=&quot;sa_cc&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;div class=&quot;sa_cc&quot;&gt;&lt;div&gt;&lt;li class=&quot;sa_wr&quot;&gt;&lt;div class=&quot;sa_cc&quot;&gt;&lt;div class=&quot;sa_mc&quot;&gt;&lt;div class=&quot;sb_tlst&quot;&gt;&lt;a href=&quot;http://www.cardiologia.org/&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span class=&quot;ske05&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;Cardiologia , Cardiologia Invasiva , Cardiologia.org&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;cite&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&amp;nbsp;- &lt;/span&gt;&lt;/span&gt;&lt;a href=&quot;http://www.cardiologia.org&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;www.cardiologia.org&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&amp;nbsp; - &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/cite&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;Cardiologia , approfondimenti in Cardiologia. ... Tra gli stent medicati presenti sul mercato fino ad oggi, lo stent a rilascio di Sirolimus ( Cypher ) ha dimostrato ...&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/li&gt;&lt;/div&gt;&lt;/div&gt;</description>
        <category>cardiologia</category>
        <category>cardiologia interventistica</category>
        <category>cardiologia invasiva</category>
        <category>cardiologia xagena</category>
        <category>cardiologia.net</category>
        <category>cardiologia.org</category>
        <category>infarto miocardico</category>
        <category>malattie cardiovascolari</category>
        <category>Malattie del cuore</category>
        <category>Newsletter Xagena</category>
            <pubDate>Mon, 14 Jan 2013 00:52:33 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11845855.html</guid>
        </item>
        <item>
            <title>Farmaci antiaritmici: Amiodarone</title>
            <link>http://blog.libero.it/XagenaMedicina/11835215.html</link>
            <description>&lt;p&gt;&lt;a href=&quot;http://www.mediline.it/articolo/104&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Amiodarone, effetti indesiderati&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;L&amp;rsquo;Amiodarone ( Cordarone, Amiodar ) &amp;egrave; un farmaco antiaritmico di classe III secondo la classificazione di Vaughan Williams. Agisce sulla fase di ripolarizzazione. L&amp;rsquo;Amiodarone trova indicazione nel trattamento delle aritmie sia ventricolari ... &lt;/strong&gt;&lt;a href=&quot;http://www.mediline.it/articolo/104&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p&gt;&lt;a href=&quot;http://www.mediline.it/articolo/393&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Studio AMIOVIRT: Amiodarone versus defibrillatore impiantabile nei pazienti con cardiomiopatia dilatativa non ischemica e tachicardia ventricolare non&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Lo studio AMIOVIRT ha confrontato la terapia con l&amp;rsquo;antiaritmico Amiodarone ed il defibrillatore impiantabile ( ICD ) nei pazienti con cardiomiopatia dilatativa non ischemica e tachicardia ventricolare non sostenuta ( TVNS ). L&amp;rsquo;end point ... &lt;/strong&gt;&lt;a href=&quot;http://www.mediline.it/articolo/393&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p&gt;&lt;a href=&quot;http://www.mediline.it/articolo/1604&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Disfunzione tiroidea durante terapia a base di Amiodarone per fibrillazione atriale persistente&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Il rischio nel lungo termine di disfunzione tiroidea indotta dall&amp;rsquo;antiaritmico Amiodarone ( Amiodar, Cordarone ) non &amp;egrave; mai stato analizzato in maniera sistematica e prospettica nei pazienti di sesso maschile. Uno studio, coordinato da Ricercatori ... &lt;/strong&gt;&lt;a href=&quot;http://www.mediline.it/articolo/1604&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;</description>
        <category>Amiodarone ( Amiodar )</category>
        <category>Amiodarone ( Cordarone )</category>
        <category>Amiodarone: effetti indesiderati</category>
        <category>Aritmie sia ventricolari</category>
        <category>aritmie xagena</category>
        <category>aritmologia xagena</category>
        <category>cardiologia xagena</category>
        <category>Cardiomiopatia dilatativa</category>
        <category>Cordarone: effetti indesiderati</category>
        <category>defibrillatore impiantabile</category>
        <category>disfunzione tiroidea</category>
        <category>Disturbi tiroidei</category>
        <category>Farmaci: Amiodarone</category>
        <category>Farmaci: Cordarone</category>
        <category>Farmaco antiaritmico</category>
        <category>fibrillazione atriale</category>
        <category>tachicardia ventricolare</category>
        <category>Terapia con Amiodarone</category>
        <category>Vaughan Williams</category>
            <pubDate>Wed, 09 Jan 2013 00:54:55 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11835215.html</guid>
        </item>
        <item>
            <title>Oncologia Notizie</title>
            <link>http://blog.libero.it/XagenaMedicina/11814585.html</link>
            <description>&lt;div class=&quot;post&quot;&gt;&lt;a href=&quot;http://www.xagena.it/index.php?view=2479&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;&lt;span style=&quot;COLOR: #ff0000&quot;&gt;&lt;font class=&quot;ske04&quot;&gt;Erbitux aggiunto alla chemioterapia non produce benefici nel tumore del colon di stadio III&lt;/font&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Verdana&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;Tra i pazienti con tumore del colon in stadio III, l'aggiunta di Erbitux ( Cetuximab ) alla chemioterapia adiuvante ( post-chirurgica ) non produce miglioramento degli esiti.Il cancro del colon di fase III si riferisce al tumore che si è diffuso ai linfonodi circostanti il colon, ma non ad altre parti dell’organismo.Cetuximab è una terapia mirat [...] &lt;/strong&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;a href=&quot;http://www.xagena.it/?view=2479&amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div&gt;&lt;font class=&quot;ske02&quot; face=&quot;Arial&quot;&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;a href=&quot;http://mediexplorer.it/&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;&lt;span style=&quot;COLOR: #ff0000&quot;&gt;&lt;span class=&quot;ske04&quot;&gt;Dabrafenib nel melanoma metastatico con mutazioni in BRAF&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Verdana&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;Dabrafenib, un inibitore di BRAF mutato, mostra attività clinica con un profilo di sicurezza gestibile in studi di fase 1 e 2 in pazienti con melanoma metastatico con mutazione BRAF(V600).Uno studio ha valutato l’efficacia di Dabrafenib in pazienti con melanoma metastatico BRAF(V600E).Nello studio in aperto di fase 3 sono stati arruolati pazienti nel p [...] &lt;/strong&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;a href=&quot;http://mediexplorer.it/&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;&lt;span style=&quot;COLOR: #ff0000&quot;&gt;&lt;span class=&quot;ske04&quot;&gt;Aumento della sopravvivenza con Enzalutamide nel carcinoma della prostata dopo chemioterapia&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Verdana&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;Enzalutamide ( Xtandi; MDV3100 ) ha come bersaglio step multipli della via di segnalazione del recettore degli androgeni, il principale determinante della crescita del tumore prostatico.È stato condotto uno studio allo scopo di valutare se Enzalutamide possa prolungare la sopravvivenza negli uomini con carcinoma della prostata resistente a castrazione dopo chemioterapia [...] &lt;/strong&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;FONT-FAMILY: Arial&quot;&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;FONT-FAMILY: arial,helvetica,sans-serif&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;</description>
        <category>BRAF mutato</category>
        <category>carcinoma prostata</category>
        <category>chemioterapia adiuvante</category>
        <category>Chemioterapia Newsletter</category>
        <category>Chemioterapia post-chirurgica</category>
        <category>Dabrafenib</category>
        <category>Dabrafenib: inibitore BRAF(V600)</category>
        <category>Enzalutamide</category>
        <category>Enzalutamide ( Xtandi )</category>
        <category>erbitux</category>
        <category>Erbitux ( Cetuximab )</category>
        <category>Erbitux e chemioterapia</category>
        <category>farmaci xagena</category>
        <category>medicina xagena</category>
        <category>Melanoma e mutazioni BRAF</category>
        <category>melanoma metastatico</category>
        <category>Melanoma Newsletter</category>
        <category>Mutazione BRAF(V600)</category>
        <category>Mutazioni nel gene BRAF</category>
        <category>Tumore colon precoce</category>
        <category>tumore metastatico</category>
        <category>tumore prostata</category>
            <pubDate>Sat, 29 Dec 2012 19:17:42 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11814585.html</guid>
        </item>
        <item>
            <title>Lazio, le emozioni by Xagena</title>
            <link>http://blog.libero.it/XagenaMedicina/11808684.html</link>
            <description>&lt;div&gt;&lt;a href=&quot;http://www.italynews.net/slideshow/Xagena/Lazio/Roma/Roma/index.html&quot; target=&quot;_blank&quot;&gt;&lt;img class=&quot;image&quot; alt=&quot;Roma 003&quot; src=&quot;http://www.italynews.net/slideshow/Xagena/Lazio/Roma/Roma/Roma%20003.jpg&quot; width=&quot;640&quot; height=&quot;480&quot; /&gt; &lt;/a&gt;&lt;/div&gt;&lt;div&gt; &lt;/div&gt;&lt;div&gt;&lt;span style=&quot;FONT-FAMILY: Arial; COLOR: #ff0000; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.italynews.net/slideshow/Xagena/Lazio/Roma/Roma/index.html&quot; target=&quot;_blank&quot;&gt;Cliccare sulla foto per altre immagini&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt; &lt;/div&gt;&lt;p&gt;&lt;span style=&quot;FONT-FAMILY: Arial; FONT-SIZE: x-small&quot;&gt;&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.emozioni.net/regions/index.php?r=/Lazio/Roma&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;Roma&lt;/font&gt;&lt;/strong&gt;&lt;/a&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/strong&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.emozioni.net/regions/index.php?r=/Lazio/Viterbo&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;Viterbo&lt;/font&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt; &lt;/p&gt;&lt;/p&gt;</description>
        <category>benessere xagena</category>
        <category>Bolsena</category>
        <category>Bolsena Xagena</category>
        <category>Borghi antichi Xagena</category>
        <category>Città di Italia</category>
        <category>emozioni xagena</category>
        <category>Gradoli</category>
        <category>Gradoli Xagena</category>
        <category>italia xagena</category>
        <category>italy xagena</category>
        <category>Lago di Bolsena</category>
        <category>lazio</category>
        <category>Lazio Xagena</category>
        <category>roma</category>
        <category>Roma Xagena</category>
        <category>salute xagena</category>
        <category>Viterbo</category>
        <category>Viterbo Xagena</category>
        <category>Vivere Italia Xagena</category>
            <pubDate>Wed, 26 Dec 2012 11:21:03 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11808684.html</guid>
        </item>
        <item>
            <title>Emilia-Romagna, le emozioni by Xagena</title>
            <link>http://blog.libero.it/XagenaMedicina/11807506.html</link>
            <description>&lt;div&gt;&lt;span style=&quot;FONT-FAMILY: Arial; FONT-SIZE: x-small&quot;&gt;&lt;a href=&quot;http://www.italynews.net/slideshow/Xagena/Emilia%20Romagna/Bologna/Crevalcore/&quot; target=&quot;_blank&quot;&gt;&lt;img class=&quot;image&quot; alt=&quot;Crevalcore (BO) 001&quot; src=&quot;http://www.italynews.net/slideshow/Xagena/Emilia%20Romagna/Bologna/Crevalcore/Crevalcore%20(BO)%20001.jpg&quot; width=&quot;640&quot; height=&quot;480&quot; /&gt;&lt;span style=&quot;FONT-FAMILY: Times New Roman; FONT-SIZE: small&quot;&gt; &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt; &lt;/div&gt;&lt;div&gt;&lt;span style=&quot;FONT-FAMILY: Arial; COLOR: #ff0000; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.italynews.net/slideshow/Xagena/Emilia%20Romagna/Bologna/Crevalcore/&quot; target=&quot;_blank&quot;&gt;Cliccare sulla foto e sui link per altre immagini&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt; &lt;/div&gt;&lt;p&gt;&lt;span style=&quot;FONT-FAMILY: Arial; FONT-SIZE: x-small&quot;&gt;&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.emozioni.net/regions/index.php?r=/Emilia Romagna/Bologna&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;Bologna&lt;/font&gt;&lt;/strong&gt;&lt;/a&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/strong&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.emozioni.net/regions/index.php?r=/Emilia Romagna/Ferrara&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;Ferrara&lt;/font&gt;&lt;/strong&gt;&lt;/a&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/strong&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.emozioni.net/regions/index.php?r=/Emilia Romagna/Modena&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;Modena&lt;/font&gt;&lt;/strong&gt;&lt;/a&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/strong&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.emozioni.net/regions/index.php?r=/Emilia Romagna/Parma&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;Parma&lt;/font&gt;&lt;/strong&gt;&lt;/a&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/strong&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.emozioni.net/regions/index.php?r=/Emilia Romagna/Piacenza&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;Piacenza&lt;/font&gt;&lt;/strong&gt;&lt;/a&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/strong&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.emozioni.net/regions/index.php?r=/Emilia Romagna/Reggio Emilia&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;Reggio Emilia&lt;/font&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;font class=&quot;ske04&quot;&gt; &lt;/font&gt;&lt;/p&gt;&lt;/p&gt;</description>
        <category>benessere xagena</category>
        <category>Bologna</category>
        <category>Bologna Foto</category>
        <category>Bologna Xagena</category>
        <category>Emilia Romagna Foto</category>
        <category>Emilia Romagna Xagena</category>
        <category>Ferrara</category>
        <category>Ferrara Foto</category>
        <category>Ferrara Xagena</category>
        <category>Modena</category>
        <category>Modena Foto</category>
        <category>Modena xagena</category>
        <category>parma</category>
        <category>Parma Foto</category>
        <category>parma xagena</category>
        <category>piacenza</category>
        <category>Piacenza Foto</category>
        <category>Piacenza Xagena</category>
        <category>Reggio Emilia</category>
        <category>Reggio Emilia Xagena</category>
        <category>Reggio-Emilia Foto</category>
            <pubDate>Tue, 25 Dec 2012 13:57:14 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11807506.html</guid>
        </item>
        <item>
            <title>Aritmie Notizie</title>
            <link>http://blog.libero.it/XagenaMedicina/11802931.html</link>
            <description>&lt;p&gt;&lt;a href=&quot;http://www.mediline.it/articolo/10&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Cardioversione elettro-farmacologica con Amiodarone o Flecainide ev nel trattamento delle aritmie ipercinetiche sopraventricolari, refrattarie al paci&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Brindicci P. Barone G., Di Tacchio N., Figliolia S., C. Piccaluga Unit&amp;agrave; Coronarica e Terapia Intensiva, Ospedale Civile L. Bonomo, Andria (BA) E&amp;rsquo; noto che con la stimolazione atriale &amp;egrave; possibile interrompere le tachiaritmie sopraventricolari ... &lt;/strong&gt;&lt;a href=&quot;http://www.mediline.it/articolo/10&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://www.mediline.it/articolo/908&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span class=&quot;ske04&quot;&gt;L&amp;rsquo;Efedrina pu&amp;ograve; causare aritmie minaccianti la vita&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Ricercatori dell&amp;rsquo;Oklahoma University hanno dimostrato in modelli animali che l&amp;rsquo;Efedrina ha effetti dannosi.L&amp;rsquo;Efedrina mina il sistema nervoso simpatico.Nell&amp;rsquo;esperimento, l&amp;rsquo;Efedrina &amp;egrave; stata data a cani con cardiopatia ischemica indotta.Dei ... &lt;/strong&gt;&lt;a href=&quot;http://www.mediline.it/articolo/908&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://www.mediline.it/articolo/1026&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Il Carvedilolo riduce le aritmie dopo infarto miocardico acuto&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;Il Carvedilolo ( Dilatrend ), un beta-bloccante, riduce le aritmie dopo infarto miocardico acuto ( IMA ).Sono stati esaminati i dati dello studio CAPRICORN ( Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction ), che ha ... &lt;/strong&gt;&lt;a href=&quot;http://www.mediline.it/articolo/1026&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</description>
        <category>amiodarone</category>
        <category>Aritmie IMA</category>
        <category>Aritmie ipercinetiche</category>
        <category>Aritmie minaccianti vita</category>
        <category>Aritmie refrattarie</category>
        <category>aritmie sopraventricolari</category>
        <category>aritmie xagena</category>
        <category>Beta-bloccante</category>
        <category>cardiopatia ischemica</category>
        <category>cardioversione farmacologica</category>
        <category>carvedilolo</category>
        <category>Carvedilolo ( Dilatrend )</category>
        <category>Efedrina</category>
        <category>flecainide</category>
        <category>Infarto miocardico acuto</category>
        <category>Medicina Newsletter</category>
        <category>Oklahoma University</category>
        <category>Trattamento aritmie</category>
        <category>xagena infarto miocardico</category>
            <pubDate>Sun, 23 Dec 2012 00:53:16 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11802931.html</guid>
        </item>
        <item>
            <title>Farmaci antinfiammatori</title>
            <link>http://blog.libero.it/XagenaMedicina/11788152.html</link>
            <description>&lt;p&gt;&lt;a href=&quot;http://www.mediline.it/articolo/2221&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;I farmaci antinfiammatori non-steroidei, compresi gli inibitori Cox-2, associati a rischio cardiovascolare &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;I comuni antidolorifici ad azione anche antinfiammatoria ( FANS ) possono aumentare il rischio di malattia cardiaca, secondo uno studio appena pubblicato.E&amp;rsquo; stata compiuta un'analisi di tutti gli studi controllati randomizzati che hanno messo ... &lt;/strong&gt;&lt;a href=&quot;http://www.mediline.it/articolo/2221&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://www.mediline.it/articolo/2295&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;I farmaci antinfiammatori associati a rischio di fibrillazione o flutter atriale &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;I farmaci antinfiammatori non-steroidei non-selettivi ( FANS ) e gli inibitori selettivi Cox-2 sono associati a un aumentato rischio di fibrillazione o flutter atriale.Uno studio, caso-controllo, basato sulla popolazione, &amp;egrave; stato realizzato ... &lt;/strong&gt;&lt;a href=&quot;http://www.mediline.it/articolo/2295&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://www.mediline.it/articolo/404&quot; target=&quot;_blank&quot;&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Gli antinfiammatori non rallentano il declino cognitivo nei pazienti con malattia di Alzheimer lieve-moderata&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;div class=&quot;excerpt&quot;&gt;&lt;p&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;strong&gt;E&amp;rsquo; stato ipotizzato che i meccanismi infiammatori contribuiscano al danno neuronale nella malattia di Alzheimer. I Ricercatori dell&amp;rsquo;Alzheimer&amp;rsquo;s Disease Cooperative Study hanno voluto verificare se il trattamento con un inibitore Cox-2, ... &lt;/strong&gt;&lt;a href=&quot;http://www.mediline.it/articolo/404&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Leggi&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</description>
        <category>Alzheimer Newsletter</category>
        <category>Anti-infiammatori</category>
        <category>antinfiammatori</category>
        <category>declino cognitivo</category>
        <category>FANS non-steroidei</category>
        <category>FANS Xagena</category>
        <category>farmaci antinfiammatori</category>
        <category>Farmaci Newsletter</category>
        <category>farmaci xagena</category>
        <category>farmacia xagena</category>
        <category>fibrillazione atriale</category>
        <category>flutter atriale</category>
        <category>inibitori cox-2</category>
        <category>malattia di alzheimer</category>
        <category>Reumatologia Newsletter</category>
        <category>rischio cardiovascolare</category>
            <pubDate>Sun, 16 Dec 2012 00:49:30 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11788152.html</guid>
        </item>
        <item>
            <title>Vaccini Notizie</title>
            <link>http://blog.libero.it/XagenaMedicina/11784062.html</link>
            <description>&lt;div class=&quot;video-content&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 28px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;ALERT Vaccini !&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 28px;&quot;&gt;&amp;nbsp;&lt;a style=&quot;line-height: 45px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.vaccini.net/index.php?view=18208&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff00ff; font-size: small;&quot;&gt;&lt;strong&gt;L&amp;rsquo;FDA ha approvato il vaccino Zostavax per prevenire l'herpes zoster in individui di 50-59 anni&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 28px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #000080; font-size: small;&quot;&gt;&lt;strong&gt;L&amp;rsquo;FDA ( Food and Drug Administration ) ha approvato l'uso di Zostavax, un vaccino a base di virus vivo attenuato, per la prevenzione dell'herpes zoster nei soggetti di et&amp;agrave; compresa tra 50e 59 anni. Zostavax &amp;egrave; gi&amp;agrave; approvato per l'impiego in soggetti di et&amp;agrave; uguale o superiore a 60 anni.Negli Stati Uniti, l&amp;rsquo;herpes zoster colpisce, ogni anno, circa 200.000 persone sane di et&amp;#65533; [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 28px;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.vaccini.net/?view=18208&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #000080; font-size: small;&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;span style=&quot;font-family: Arial; color: #000080; font-size: small;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&amp;nbsp;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; font-size: small;&quot;&gt;&lt;strong&gt;VACCINAZIONE CONTRO PAPILLOMAVIRUS&lt;/strong&gt;&lt;/span&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #000080; font-size: small;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&amp;nbsp;&lt;div class=&quot;ecxpost-content&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.vaccini.net/index.php?page=2&amp;amp;view=15879&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff00ff; font-size: medium;&quot;&gt;&lt;strong&gt;Sicurezza, immunogenicit&amp;agrave; ed efficacia del vaccino quadrivalente anti-HPV nelle donne di et&amp;agrave; compresa tra 25 e 45 anni&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #000080; font-size: small;&quot;&gt;&lt;strong&gt;Bench&amp;egrave; il picco di incidenza dell&amp;rsquo;infezione da HPV ( papillomavirus umano ) si verifichi nella maggior parte della popolazione tra i 5 e i 10 anni dalla prima esperienza sessuale, tutte le donne restano a rischio di infettarsi.Un gruppo di Ricercatori colombiani ha testato la sicurezza, l&amp;rsquo;immunogenicit&amp;agrave; e l&amp;rsquo;efficacia del vaccino quadrivalente per l&amp;rsquo;HPV ( tipi 6, 11, 16 [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.vaccini.net/index.php?view=15879&amp;amp;page=2&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #000080; font-size: small;&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #000080; font-size: small;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #000080; font-size: small;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.vaccini.net/index.php?page=4&amp;amp;view=15548&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff00ff; font-size: medium;&quot;&gt;&lt;strong&gt;Nuova indicazione per Gardasil dall&amp;rsquo;FDA: prevenzione dei condilomi acuminati nei soggetti di sesso maschile&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #000080; font-size: small;&quot;&gt;&lt;strong&gt;L&amp;rsquo;FDA ( Food and Drug Administration ) ha approvato l&amp;rsquo;impiego del vaccino Gardasil per la prevenzione dei condilomi acuminati dovuti ai sierotipi 6 e 11 di papillomavirus umano ( HPV ) nei ragazzi e negli uomini di et&amp;agrave; compresa tra 9 e 26 anni.Negli Stati Uniti, ogni anno, 2 uomini su 1.000, approssimativamente, ricevono nuova diagnosi di condiloma acuminato.Gard [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.vaccini.net/index.php?view=15548&amp;amp;page=4&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #000080; font-size: small;&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</description>
        <category>ALERT Vaccini</category>
        <category>herpes zoster</category>
        <category>papillomavirus</category>
        <category>papillomavirus umano</category>
        <category>Sicurezza vaccini</category>
        <category>vaccinazione papillomavirus</category>
        <category>vaccini</category>
        <category>Vaccini ALERT; Vaccini News</category>
        <category>vaccini xagena</category>
        <category>vaccino anti-hpv</category>
        <category>vaccino quadrivalente</category>
        <category>Vaccino Zostavax</category>
        <category>Virus HPV</category>
        <category>zostavax</category>
            <pubDate>Fri, 14 Dec 2012 00:23:45 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11784062.html</guid>
        </item>
        <item>
            <title>Ematologia Notizie</title>
            <link>http://blog.libero.it/XagenaMedicina/11767004.html</link>
            <description>&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;div style=&quot;WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; FONT: 13px/17px Tahoma, Verdana, Arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #2a2a2a; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;ecxpost&quot;&gt;&lt;a style=&quot;LINE-HEIGHT: 28px; COLOR: #006e12 !important; CURSOR: pointer; TEXT-DECORATION: underline&quot; href=&quot;http://mediexplorer.it/&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;Ruxolitinib, un inibitore JAK in pazienti con leucemia refrattaria, compresa la leucemia mieloide acuta post neoplasia mieloproliferativa&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div style=&quot;WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; FONT: 13px/17px Tahoma, Verdana, Arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #2a2a2a; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;ecxpost&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-content&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;È stato condotto uno studio di fase 2 riguardante Ruxolitinib ( Jakafi ), un inibitore delle Janus chinasi ( JAK ), in pazienti con leucemie recidivate o refrattarie. I pazienti con performance status accettabile ( 0-2 ), adeguata funzione di organo e nessuna infezione attiva hanno ricevuto Ruxolitinib 25 mg per via orale 2 volte al giorno per 4 settimane ( 1 ciclo ). [...]&lt;/span&gt; &lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-more&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-more&quot;&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=&quot;WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; FONT: 13px/17px Tahoma, Verdana, Arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #2a2a2a; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;ecxpost&quot;&gt;&lt;a style=&quot;LINE-HEIGHT: 28px; COLOR: #006e12 !important; CURSOR: pointer; TEXT-DECORATION: underline&quot; href=&quot;http://mediexplorer.it/&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;La combinazione di Bendamustina, Lenalidomide e Desametasone in pazienti con mieloma multiplo recidivo o refrattario è efficace&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div style=&quot;WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; FONT: 13px/17px Tahoma, Verdana, Arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #2a2a2a; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;ecxpost&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-content&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;Uno studio multicentrico di fase 1/2 ha studiato l'associazione di Bendamustina ( Levact ), Lenalidomide ( Revlimid ) e Desametasone ( Decadron ) in cicli di 4 settimane ripetuti, come trattamento per il mieloma multiplo recidivato refrattario.Nella fase 1 è stata stabilita la dose massima tollerata ( MTD ). La fase 2 ha valutato il tasso complessivo di risposta a [...]&lt;/strong&gt;&lt;/span&gt; &lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-more&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-more&quot;&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=&quot;WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; FONT: 13px/17px Tahoma, Verdana, Arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #2a2a2a; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;ecxpost&quot;&gt;&lt;a style=&quot;LINE-HEIGHT: 28px; COLOR: #006e12 !important; CURSOR: pointer; TEXT-DECORATION: underline&quot; href=&quot;http://mediexplorer.it/&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;Studio di fase 1 di Obinutuzumab, anticorpo monoclonale umanizzato glicoingegnerizzato di tipo II anti-CD20 in pazienti affetti da linfoma a cellule B&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div style=&quot;WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; FONT: 13px/17px Tahoma, Verdana, Arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #2a2a2a; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;ecxpost&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-content&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;L'anticorpo chimerico di tipo I anti-CD20 Rituximab ha migliorato in maniera significativa gli esiti per i pazienti con tumori maligni a cellule B; tuttavia molti pazienti con linfoma non-Hodgkin ( NHL ) rimangono incurabili.Obinutuzumab ( GA101 ) è un anticorpo umanizzato glicoingegnerizzato di tipo II anti-CD20 che ha dimostrato attività superiore rispetto agli [...]&lt;/strong&gt;&lt;/span&gt; &lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-more&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;</description>
        <category>Anti-CD20 Rituximab</category>
        <category>Anticorpo chimerico</category>
        <category>anticorpo monoclonale</category>
        <category>Bendamustina</category>
        <category>Bendamustina ( Levact )</category>
        <category>desametasone</category>
        <category>Desametasone ( Decadron )</category>
        <category>Inibitore JAK</category>
        <category>Inibitore Janus chinasi ( JAK )</category>
        <category>lenalidomide</category>
        <category>Lenalidomide ( Revlimid )</category>
        <category>leucemia mieloide</category>
        <category>Leucemia refrattaria</category>
        <category>Leucemie recidivate</category>
        <category>Leucemie refrattarie</category>
        <category>Linfoma a cellule B</category>
        <category>linfoma non-hodgkin</category>
        <category>mieloma multiplo</category>
        <category>Neoplasia mieloproliferativa</category>
        <category>Obinutuzumab</category>
        <category>Obinutuzumab ( GA101 )</category>
        <category>Ruxolitinib</category>
        <category>Ruxolitinib ( Jakafi )</category>
        <category>Tumori maligni a cellule B</category>
            <pubDate>Thu, 06 Dec 2012 00:57:02 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11767004.html</guid>
        </item>
        <item>
            <title>Ipertensione News</title>
            <link>http://blog.libero.it/XagenaMedicina/11751633.html</link>
            <description>&lt;div&gt;&lt;span style=&quot;FONT-FAMILY: Arial; FONT-SIZE: x-small&quot;&gt;&lt;div style=&quot;WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; FONT: 13px/17px Tahoma, Verdana, Arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #2a2a2a; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;ecxpost-more&quot;&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost&quot;&gt;&lt;a style=&quot;LINE-HEIGHT: 28px; COLOR: #006e12 !important; CURSOR: pointer; TEXT-DECORATION: underline&quot; href=&quot;http://www.medicinanews.it/index.php?view=2516&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;&lt;span style=&quot;COLOR: #ff0000&quot;&gt;L'ipertensione in gravidanza può influenzare le capacità cognitive del nascituro nella età avanzata&lt;/span&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost&quot;&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-content&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske03&quot;&gt;I risultati di uno studio finlandese hanno mostrato che i disturbi ipertensivi durante la gravidanza possono predire un aumento del declino cognitivo e più ridotta capacità cognitiva nella vecchiaia.Sono state esaminate le cartelle cliniche di 398 uomini nello studio Helsinki Birth Cohort 1934-1944.Le gravidanze delle madri sono state classificate com [...]&lt;/font&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-more&quot;&gt;&lt;a style=&quot;LINE-HEIGHT: 17px; COLOR: #0068cf; CURSOR: pointer; TEXT-DECORATION: underline&quot; href=&quot;http://www.medicinanews.it/?view=2516&amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske03&quot;&gt;Leggi articolo completo&lt;/font&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=&quot;WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; FONT: 13px/17px Tahoma, Verdana, Arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #2a2a2a; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px&quot; class=&quot;ecxpost-more&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-SIZE: x-small&quot;&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost&quot;&gt;&lt;a style=&quot;LINE-HEIGHT: 27px; COLOR: #006e12 !important; CURSOR: pointer; TEXT-DECORATION: underline&quot; href=&quot;http://www.ipertensione.net/index.php?view=21530&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske03&quot;&gt;&lt;span style=&quot;COLOR: #ff0000&quot;&gt;&lt;font class=&quot;ske04&quot;&gt;Soglie di pressione sanguigna monitorata nelle 24 ore associata a complicanze croniche nel diabete mellito di tipo 2&lt;/font&gt;&lt;/span&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost&quot;&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-content&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske03&quot;&gt;I valori di cut-off diagnostici per il monitoraggio nelle 24 ore della pressione arteriosa ( ABPM ) in pazienti diabetici non sono stabiliti.Uno studio ha esaminato le associazioni tra pressione sanguigna rilevata presso lo studio medico e pressione sanguigna rilevata con monitoraggio nelle 24 ore e le complicazioni croniche del diabete mellito per stabilire i valori soglia ot [...]&lt;/font&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-more&quot;&gt;&lt;a style=&quot;LINE-HEIGHT: 17px; COLOR: #0068cf; CURSOR: pointer; TEXT-DECORATION: underline&quot; href=&quot;http://www.ipertensione.net/?view=21530&amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske03&quot;&gt;Leggi articolo completo&lt;/font&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-more&quot;&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-more&quot;&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;&lt;span style=&quot;COLOR: #ff0000&quot;&gt;&lt;a style=&quot;LINE-HEIGHT: 27px; COLOR: #006e12 !important; CURSOR: pointer; TEXT-DECORATION: underline&quot; href=&quot;http://mediexplorer.it/&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske04&quot;&gt;&lt;span style=&quot;COLOR: #ff0000&quot;&gt;Indice di massa corporea materno, altezza e rischi di preeclampsia&lt;/span&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt; &lt;/span&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;font color=&quot;#000000&quot; class=&quot;ske02&quot;&gt;&lt;span style=&quot;COLOR: #ff0000&quot;&gt;&lt;/span&gt;&lt;/font&gt;&lt;/span&gt; &lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost&quot;&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxg-plusone&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-content&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;font class=&quot;ske03&quot;&gt;Esiste una associazione tra indice di massa corporea materno ( BMI ) e preeclampsia, ma rimane questione controversa l’ipotesi che l’indice di massa corporea abbia un effetto su tutti i gradi di preeclampsia. Non è noto se esiste una associazione tra altezza materna e tutti i gradi di preeclampsia.In questo studio di coorte basato sulla popolazione che [...]&lt;/font&gt;&lt;/strong&gt;&lt;/span&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost-more&quot;&gt;&lt;div style=&quot;LINE-HEIGHT: 17px&quot; class=&quot;ecxpost&quot;&gt;&lt;span style=&quot;LINE-HEIGHT: normal; FONT-FAMILY: Arial; FONT-SIZE: medium&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;</description>
        <category>cardiologia xagena</category>
        <category>declino cognitivo</category>
        <category>diabete mellito</category>
        <category>Disturbi cognitivi</category>
        <category>Disturbi ipertensivi</category>
        <category>gravidanza</category>
        <category>Indice BMI</category>
        <category>Indice massa corporea</category>
        <category>ipertensione gravidanza</category>
        <category>Ipertensione news</category>
        <category>ipertensione xagena</category>
        <category>Newsletter Ipertensione</category>
        <category>preeclampsia</category>
        <category>pressione sanguigna</category>
        <category>Rischio di preeclampsia</category>
            <pubDate>Thu, 29 Nov 2012 00:36:56 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11751633.html</guid>
        </item>
        <item>
            <title>Osteoporosi Notizie</title>
            <link>http://blog.libero.it/XagenaMedicina/11733216.html</link>
            <description>&lt;div&gt;&lt;p style=&quot;widows: 2; text-transform: none; text-indent: 0px; margin: 0px 0px 1.35em; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: arial, helvetica, sans-serif;&quot;&gt;&lt;span style=&quot;line-height: normal; font-size: x-large;&quot;&gt;Altre News&lt;/span&gt;&lt;span class=&quot;Apple-converted-space&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: normal; font-size: x-large;&quot;&gt;&lt;span style=&quot;line-height: normal; background-color: #ff0000; color: #ffffff;&quot;&gt;&amp;gt;&lt;/span&gt;&amp;nbsp;Osteoporosi&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;span style=&quot;widows: 2; text-transform: none; text-indent: 0px; font: x-large Arial; white-space: normal; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;a style=&quot;line-height: 68px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaexplorer.it/articolo/18664&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: small;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Rischio potenziale di tumore dell&amp;rsquo;esofago con l&amp;rsquo;assunzione prolungata dei farmaci anti-osteoporosi somministrati per bocca&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;ecxexcerpt&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;p style=&quot;line-height: 41px; margin: 0px 0px 1.35em;&quot;&gt;&lt;span style=&quot;line-height: normal;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;&lt;span class=&quot;ske06&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;Ci sono informazioni contrastanti sulla relazione tra impiego dei farmaci bifosfonati orali e probabilit&amp;agrave; di sviluppare il cancro esofageo.I bifosfonati sono farmaci utilizzati nella profilassi e nel trattamento dell&amp;rsquo;osteoporosi, anche di quella ...&lt;span class=&quot;Apple-converted-space&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 23px;&quot;&gt;&lt;a style=&quot;line-height: 23px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaexplorer.it/articolo/18664&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;span style=&quot;line-height: 41px;&quot;&gt;&lt;a style=&quot;line-height: 68px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaexplorer.it/articolo/19866&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: small;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Assunzione di Calcio con la dieta e rischio di fratture e di osteoporosi&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;ecxexcerpt&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;p style=&quot;line-height: 41px; margin: 0px 0px 1.35em;&quot;&gt;&lt;span style=&quot;line-height: normal;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;&lt;span class=&quot;ske06&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;Uno studio di coorte longitudinale e prospettico ha indagato le associazioni tra assunzione a lungo termine di Calcio nella dieta e rischio di fratture di qualsiasi tipo, fratture dell'anca e osteoporosi.La studio si &amp;egrave; basato sulla ...&lt;span class=&quot;Apple-converted-space&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 23px;&quot;&gt;&lt;a style=&quot;line-height: 23px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaexplorer.it/articolo/19866&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;&lt;a style=&quot;line-height: 68px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaexplorer.it/articolo/17907&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: small;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;La&lt;span style=&quot;color: #ff0000;&quot;&gt;sofoxifene ed eventi cardiovascolari in donne con osteoporosi in postmenopausa&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;ecxexcerpt&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;p style=&quot;line-height: 41px; margin: 0px 0px 1.35em;&quot;&gt;&lt;span class=&quot;ske06&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;&lt;span style=&quot;line-height: normal;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Nello studio PEARL ( Postmenopausal Evaluation and Risk Reduction With Lasofoxifene ), donne assegnate a Lasofoxifene ( Fablyn ) 0.5 mg/giorno hanno mostrato un rischio pi&amp;ugrave; basso di eventi di malattia coronarica maggiore e ictus, mentre ...&lt;span class=&quot;Apple-converted-space&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 23px;&quot;&gt;&lt;a style=&quot;line-height: 23px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaexplorer.it/articolo/17907&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;line-height: 41px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;a style=&quot;line-height: 68px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaexplorer.it/articolo/16319&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: small;&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske04&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Denosumab nella prevenzione delle fratture in donne in postmenopausa con osteoporosi&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;ecxexcerpt&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;p style=&quot;line-height: 41px; margin: 0px 0px 1.35em;&quot;&gt;&lt;span style=&quot;line-height: normal;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;&lt;span class=&quot;ske06&quot;&gt;&lt;strong&gt;&lt;span class=&quot;ske03&quot;&gt;Denosumab ( Prolia ) &amp;egrave; un anticorpo monoclonale umano contro RANKL ( receptor activator of nuclear factor-kappaB ligand ), che agisce inibendo lo sviluppo e l&amp;rsquo;attivit&amp;agrave; degli osteoclasti, diminuendo il riassorbimento osseo e ...&lt;span class=&quot;Apple-converted-space&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 23px;&quot;&gt;&lt;a style=&quot;line-height: 23px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaexplorer.it/articolo/16319&quot; target=&quot;_blank&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;</description>
        <category>Anticorpo contro RANKL</category>
        <category>anticorpo monoclonale</category>
        <category>Bifosfonati: osteoporosi</category>
        <category>Calcio con la dieta</category>
        <category>Cancro esofageo</category>
        <category>Denosumab ( Prolia )</category>
        <category>Denosumab: osteoporosi</category>
        <category>Donne con osteoporosi</category>
        <category>Farmaci anti-osteoporosi</category>
        <category>Farmaci: bifosfonati orali</category>
        <category>Fratture e osteoporosi</category>
        <category>Lasofoxifene ( Fablyn )</category>
        <category>Lasofoxifene: cardiovascolare</category>
        <category>News Osteoporosi</category>
        <category>Osteoporosi in menopausa</category>
        <category>Osteoporosi Newsletter</category>
        <category>Osteoporosi Notizie</category>
        <category>osteoporosi xagena</category>
        <category>Prevenzione fratture</category>
        <category>Profilassi osteoporosi</category>
        <category>Trattamento osteoporosi</category>
        <category>tumore esofago</category>
            <pubDate>Tue, 20 Nov 2012 23:42:22 +0200</pubDate>
            <guid>http://blog.libero.it/XagenaMedicina/11733216.html</guid>
        </item>
    </channel>
</rss>
